Arca
Skip to content
Tools
Tools

Imatinib Mesylate Tablets 100 mg

Recall D-0124-2021, part of FDA recall event 86749. See Shilpa Medicare's company page.

Shilpa Medicare Limited started this Class II drug recall on Dec 8, 2020 (voluntary: firm initiated); FDA lists it as terminated, terminated Mar 11, 2022.

  • Classification: Class II
  • Started: Dec 8, 2020
  • Status: Terminated
  • Products in this event: 6

Why It Was Recalled

Class II

CGMP Deviations

Record

Product
Imatinib Mesylate Tablets 100 mg, Rx Only, 90-count Bottle, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals Inc., Manalapan, NJ 07726, NDC 72485-202-90.
Quantity
2611 bottles
Lots and codes
Lot #s: 7S10033B, 7S10033A, 7S10031A, Exp. 02/28/2021.
Distribution
Nationwide in the U.S.
Recalling firm
Shilpa Medicare Limited, Polepally, Jadcherla, N/A, India
How the firm notified
Letter
FDA classified
Dec 9, 2020

Other Products in This Recall

Recall event 86749

Shilpa Medicare Limited's Other Recalls

Newest first, one product per recall event; search them all

FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.